Sulfonylureas stimulate insulin secretion regardless of the serum glucose levels.

Weight gain is common with sulfonylureas.

Other common side effects include nausea, diarrhea, dizziness, and headache.

The University Group Diabetes Program (UGDP) trial showed an increased risk of mortality with tolbutamide.

Glimepiride is not associated with an increased cardiovascular risk.

The ADA guideline recommends metformin as a first-line agent for all patients with type 2 diabetes unless contraindicated.